Buprenorphine and Dipyrone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Dipyrone
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking buprenorphine (like Belbuca, Suboxone, or Sublocade) together with dipyrone, a pain and fever medicine. Dipyrone can speed up the liver enzyme that breaks down buprenorphine. That means your body may clear the buprenorphine faster, so there's less of it working in your system.
For someone on buprenorphine, that can mean your pain is not as well controlled, or you may feel opioid withdrawal, things like restlessness, sweating, chills, or an upset stomach. The good news is this is manageable. Do not change anything on your own. Talk with your pharmacist or doctor, who can adjust your dose and watch you closely so you stay comfortable.
Effect: Dipyrone (a probable CYP3A4 inducer) may increase CYP3A4-mediated metabolism of buprenorphine, lowering buprenorphine plasma concentrations, AUC, and efficacy. Buprenorphine is the active drug (not a prodrug), so induction reduces its opioid effect and can precipitate withdrawal.
- Direction: reduced buprenorphine exposure/efficacy
- Onset: unspecified; Evidence: probable; Severity: major
- Management: If the inducer is needed, titrate buprenorphine upward to stable effect and monitor for withdrawal. On inducer discontinuation, consider dose reduction and monitor for respiratory depression. Use formulations allowing precise titration; for subQ depot, monitor adequacy of levels or for withdrawal.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Because a CYP3A4 inducer lowers buprenorphine plasma concentrations, giving one alongside buprenorphine can precipitate opioid withdrawal symptoms. When a CYP3A4 inducer must be added for a patient taking buprenorphine, consider raising the buprenorphine dose until stable drug effects are reached, while watching for withdrawal. Conversely, if a CYP3A4 inducer is stopped in someone on buprenorphine, consider lowering the buprenorphine dose and observe for respiratory depression2. Should dose adjustment prove impossible once the CYP3A4 inducer is gone, move the patient back to a buprenorphine formulation that allows finer dose titration. For patients switched from transmucosal buprenorphine that was given together with CYP3A4 inducers, confirm through monitoring that the plasma buprenorphine achieved with subQ buprenorphine is sufficient. In those already receiving subQ buprenorphine who need a CYP3A4 inducer, watch for withdrawal. When the buprenorphine dose is insufficient while the concomitant drug is present, and that concomitant drug cannot be reduced or stopped, adjust the buprenorphine dose. If the available doses cannot deliver the target dose, use a buprenorphine formulation that allows more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Because dipyrone can lower how much buprenorphine is active in your body, your team may:
- Adjust your buprenorphine dose, individualized until you feel stable
- Monitor you more closely for withdrawal signs (restlessness, sweating, chills, nausea, aches)
- Watch you carefully if dipyrone is later stopped, since your buprenorphine level may then rise
- Consider a buprenorphine formulation that allows more precise dose adjustments if needed
Let your pharmacist or prescriber know you take both, and report any withdrawal symptoms or changes in your pain control.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, interactions of this kind have been documented in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Dipyrone together?
Dipyrone can lower buprenorphine levels and trigger reduced pain relief or opioid withdrawal, so ask your care team to monitor you and adjust your dose rather than changing anything yourself. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Dipyrone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Dipyrone interaction managed?
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Because dipyrone can lower how much buprenorphine is active in your body, your team may: Adjust your buprenorphine dose, individualized until you feel stable Monitor you more closely for withdrawal signs (restlessness, sweating, chills, nausea, aches) Watch you carefully if dipyrone is later stopped, since… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Dipyrone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Dipyrone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist